Furthermore, dasatinib-treated CML patients have a higher proportion of effector CD4+ T cells that differentiate into Th1-type cytokine producers and are capable of producing IFN-γ, which is key for tumor control (80). The gene discussed is CD4; the disease is neoplasm.